Daptomycin is a lipopeptide antibiotic active against gram-positive bacteria indicated for the treatment of complicated skin and skin structure infections and Staphylococcus aureus bloodstream infections, including endocarditis. Thrombocytopaenia, but not neutropaenia, is described as a possible or probable adverse effect in the product information. Up to now, two case reports of daptomycin-induced thrombocytopaenia have been published and a single case of neutropaenia associated with prolonged daptomycin use.
View Article and Find Full Text PDF